News Releases

August 16, 2021
LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant prostate cancer; on track to begin later this year Collaboration with Janssen Biotech, Inc.
» Full Release
July 27, 2021
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary
UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced the appointment of Amy
» Full Release
July 13, 2021
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia UTRECHT, The Netherlands and PHILADELPHIA, July 13, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on
» Full Release
May 25, 2021
LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive
» Full Release
May 20, 2021
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 Clinical development plans on schedule in both hematological and solid tumor programs Leadership strengthened through key management and board appointments
» Full Release
May 18, 2021
LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive
» Full Release
April 1, 2021
LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCEs) to transform cancer therapy, today announced that Karen J.
» Full Release
March 24, 2021
LAVA Therapeutics Announces Pricing of Initial Public Offering
UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of its initial public
» Full Release
March 15, 2021
LAVA Therapeutics B.V. Appoints Edward F. Smith as Chief Financial Officer
Veteran biopharma CFO brings over 20 years of experience leading finance functions at publicly traded pharmaceutical companies Utrecht, The Netherlands and Philadelphia, USA – March 15, 2021 – LAVA Therapeutics B.V. (“LAVA”, or the “Company”), a biotechnology company focused on applying its
» Full Release
March 10, 2021
LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting
Utrecht, The Netherlands and Philadelphia, USA – March 10, 2021 – LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bs TCE) to transform cancer therapy, today announced that a poster featuring lead clinical candidate
» Full Release